vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and Rimini Street, Inc. (RMNI). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $105.5M, roughly 2.0× Rimini Street, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 1.3%, a 56.1% gap on every dollar of revenue.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Rimini Street, Inc. is a global provider of independent third-party support services for enterprise software products including Oracle and SAP platforms. It serves clients across multiple industries worldwide, delivering cost-effective support, maintenance, and consulting solutions that help businesses cut operational expenses while ensuring software performance and security.
IDYA vs RMNI — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $105.5M |
| Net Profit | $119.2M | $1.4M |
| Gross Margin | — | 59.0% |
| Operating Margin | 52.2% | 4.6% |
| Net Margin | 57.4% | 1.3% |
| Revenue YoY | — | 1.2% |
| Net Profit YoY | 330.1% | -59.4% |
| EPS (diluted) | $1.33 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $105.5M | ||
| Q4 25 | — | $109.8M | ||
| Q3 25 | $207.8M | $103.4M | ||
| Q2 25 | — | $104.1M | ||
| Q1 25 | — | $104.2M | ||
| Q4 24 | — | $114.2M | ||
| Q3 24 | $0 | $104.7M | ||
| Q2 24 | $0 | $103.1M |
| Q1 26 | — | $1.4M | ||
| Q4 25 | — | $724.0K | ||
| Q3 25 | $119.2M | $2.8M | ||
| Q2 25 | — | $30.3M | ||
| Q1 25 | — | $3.4M | ||
| Q4 24 | — | $6.7M | ||
| Q3 24 | $-51.8M | $-43.1M | ||
| Q2 24 | $-52.8M | $-1.1M |
| Q1 26 | — | 59.0% | ||
| Q4 25 | — | 60.4% | ||
| Q3 25 | — | 59.9% | ||
| Q2 25 | — | 60.4% | ||
| Q1 25 | — | 61.0% | ||
| Q4 24 | — | 63.7% | ||
| Q3 24 | — | 60.7% | ||
| Q2 24 | — | 59.1% |
| Q1 26 | — | 4.6% | ||
| Q4 25 | — | 4.5% | ||
| Q3 25 | 52.2% | 4.2% | ||
| Q2 25 | — | 39.6% | ||
| Q1 25 | — | 9.0% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | — | -47.4% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | 1.3% | ||
| Q4 25 | — | 0.7% | ||
| Q3 25 | 57.4% | 2.7% | ||
| Q2 25 | — | 29.1% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | — | -41.2% | ||
| Q2 24 | — | -1.1% |
| Q1 26 | — | $0.01 | ||
| Q4 25 | — | $0.00 | ||
| Q3 25 | $1.33 | $0.03 | ||
| Q2 25 | — | $0.32 | ||
| Q1 25 | — | $0.04 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $-0.60 | $-0.47 | ||
| Q2 24 | $-0.68 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | $132.2M |
| Total DebtLower is stronger | — | $56.4M |
| Stockholders' EquityBook value | $1.1B | — |
| Total Assets | $1.2B | $397.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $132.2M | ||
| Q4 25 | — | $120.0M | ||
| Q3 25 | $786.9M | $108.7M | ||
| Q2 25 | — | $101.3M | ||
| Q1 25 | — | $122.6M | ||
| Q4 24 | — | $88.8M | ||
| Q3 24 | $920.0M | $119.5M | ||
| Q2 24 | $701.7M | $134.2M |
| Q1 26 | — | $56.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $-27.0M | ||
| Q3 25 | $1.1B | $-27.3M | ||
| Q2 25 | — | $-29.0M | ||
| Q1 25 | — | $-63.7M | ||
| Q4 24 | — | $-69.4M | ||
| Q3 24 | $1.2B | $-76.8M | ||
| Q2 24 | $931.7M | $-36.1M |
| Q1 26 | — | $397.1M | ||
| Q4 25 | — | $423.1M | ||
| Q3 25 | $1.2B | $352.9M | ||
| Q2 25 | — | $397.5M | ||
| Q1 25 | — | $343.0M | ||
| Q4 24 | — | $369.1M | ||
| Q3 24 | $1.2B | $343.8M | ||
| Q2 24 | $973.7M | $367.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | — |
| Free Cash FlowOCF − Capex | $142.2M | — |
| FCF MarginFCF / Revenue | 68.4% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $19.6M | ||
| Q3 25 | $142.2M | $24.7M | ||
| Q2 25 | — | $-17.8M | ||
| Q1 25 | — | $33.7M | ||
| Q4 24 | — | $-37.7M | ||
| Q3 24 | $-49.2M | $-18.5M | ||
| Q2 24 | $-32.9M | $6.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $18.9M | ||
| Q3 25 | $142.2M | $23.5M | ||
| Q2 25 | — | $-19.5M | ||
| Q1 25 | — | $32.8M | ||
| Q4 24 | — | $-38.4M | ||
| Q3 24 | $-49.7M | $-19.2M | ||
| Q2 24 | $-33.9M | $5.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 17.2% | ||
| Q3 25 | 68.4% | 22.7% | ||
| Q2 25 | — | -18.8% | ||
| Q1 25 | — | 31.5% | ||
| Q4 24 | — | -33.6% | ||
| Q3 24 | — | -18.3% | ||
| Q2 24 | — | 5.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.6% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 0.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 27.02× | ||
| Q3 25 | 1.19× | 8.94× | ||
| Q2 25 | — | -0.59× | ||
| Q1 25 | — | 10.06× | ||
| Q4 24 | — | -5.66× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
